S NCBI Pub Med	A service of the National Library of Medicine and the National Institutes of Health [Sign In] [Regis:
All Databases PubMed Nucleotide Protein	Genome Structure OMIM PMC Journals Book
Search PubMed for antiplatelet so	lid tumor Go Clear
Limits Preview/Index History Clipboard Note: Performing your original search, antiple	Details atelet solid tumor, in PubMed will retrieve 4
citations.	Sort by Send to
Display AbstractPlus Show 20 All: 1 Review: 0	Soft by Page 10 to 10

1: Angiogenesis. 1999;3(1):53-60.

Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro).

Varner JA, Nakada MT, Jordan RE, Coller BS.

Department of Medicine, Cellular and Molecular Medicine East 3050, University of California, San Diego, La Jolla, CA 92093-0684, USA. jvarner@ucsd.edu

Angiogenesis plays an essential role in the growth and dissemination of solid tumor cancers. The expression of endothelial cell integrin alpha(v)beta3 has been shown to increase during vascular proliferation associated with human tumors. Selective antagonists of alpha(v)beta3 can block angiogenesis and tumor growth by inducing programmed cell death in proliferating endothelial cells. Monoclonal antibody 7E3, an antagonist of the human, but not murine, integrins alpha(v)beta3 and alphaIIbbeta3 (GPIIb/IIIa), inhibits platelet aggregation. It is the parent antibody of a mouse/human chimeric antibody fragment approved for adjunctive therapy of patients undergoing percutaneous coronary interventions to prevent ischemic complications (c7E3Fab; abciximab; ReoPro). To evaluate the potential of 7E3 to inhibit human angiogenesis and tumor growth independent of its antiplatelet effects, we established integrin alpha(v)beta3-negative human melanoma tumors in full-thickness human skin grafted onto SCID mice. The resulting tumors induce a human angiogenic response as assessed by the immunoreactivity of vascular cells with monoclonal antibodies specific for human CD31. Administration of 7E3 prevented or significantly inhibited the growth of tumors, and this effect correlated with a significant reduction in the number of blood vessels supplying the tumors. These results support the previous findings that blockade of integrin alpha(v)beta3 inhibits angiogenesis and tumor growth and indicates that dual inhibitors of alpha(v)beta3 and alphaIIbbeta3 are effective in blocking tumor growth and angiogenesis.



Related Links

Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. [Cancer Res. 2002]

Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v) beta3 integrins. [Circulation, 1998]

A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. [Cancer Res. 1998]

Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological[PadioBinus Res. 2000]

c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenog[Afgrogedesis. 2006]

See all Related Articles...

PMID: 14517444 [PubMed]

Display AbstractPlus Show 20 Sort by Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Apr 4 2007 12:47:27

S	NCB	
	tabases	Publ
Search	PubMed	
Limits	∨ Previ	ew/Ind



A service of the National Library of Medicine and the National Institutes of Health

My NCBI [Sign In] [Regis:

All Databases	PubMed	Nucleotide	Protein	Genome	Structure	ОМІМ	PMC	Journals	Воо
Search PubMed		for _					Go	Clear	
Limits Previe	ew/Index	History	Clipboard	✓ Details	`	1			
Display AbstractPl	us	. SI	10w 20 🕒	Sort by	▼ Send to				
All: 1 Review:	1 🔀								

1: Pathol Oncol Res. 2000;6(3):163-74.

athol ncol es

Links

Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications.

Cohen SA, Trikha M, Mascelli MA.

Cenrocor Inc. 200 Great Valley Parkway, Malvern, PA 19355, USA.,

Abciximab (ReoPro) is a mouse-human chimeric monoclonal antibody Fab fragment of the parent murine monoclonal antibody 7E3, and was the first of these agents approved for use as adjunct therapy for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention (PCI). Abciximab binds with high avidity to both the non-activated and activated form of the GPIIb/IIIa receptor of platelets, the major adhesion receptor involved in aggregation. Additional cardiovascular indications for abciximab are unstable angina, carotid stenting, ischemic stroke and peripheral vascular diseases. Abciximab also interacts with two other integrin receptors; the a av b b3 receptor, which is present in low numbers on platelets but in high density on activated endothelial and smooth muscle cells, and a aMb b2 integrin which is present on activated leukocytes. Cell types that express integrins GPIIb/IIIa and a av b b3 such as platelets, endothelial and tumor cells have been implicated in angiogenesis, tumor growth and metastasis. Since abciximab interacts with high avidity to integrins GPIIb/IIIa and a av b b3, it is reasonable to assume that it may possess anti-angiogenic properties in angiogenesis-related diseases, as well as anti-metastastatic properties in case of disseminating tumors expressing the target integrin receptors.

PMID: 11033455 [PubMed - indexed for MEDLINE]

Related Links

Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and flowing adding etio 2002]

The anti-GPIIb-IIIa agents: fundamental and clinical caspact 19961

Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and bindingsproparties. 20021

Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularitationardiovasc Drugs. 2003]

ABCIXIMAB: a new antiaggregant used in angiop**hasty**harmacother. 1996]

See all Related Articles...

Display AbstractPlus Show 20 Sort by Send to

> Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

> > Apr 4 2007 12:47:27

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1960	clopidogrel	US-PGPUB; USPAT	OR	QΝ	2007/04/20 10:29
L2	202556	((solid adj tumor) or oma or cancer or tumour or tumor or carcinoma or sarcoma)	US-PGPUB; USPAT	OR	ON	2007/04/20 10:31
L3	221735	((solid adj tumor) or ?oma or cancer or tumour or tumor or carcinoma or sarcoma)	US-PGPUB; USPAT	OR	ON :	2007/04/20 10:31
L4	1268	I1 and I2	US-PGPUB; USPAT	OR	ON	2007/04/20 10:31
L5	1098	l4 and (platelet)	US-PGPUB; USPAT	OR	ON	2007/04/20 10:31
L6	204	l4 and (platelet)	USPAT	OR	ÓΝ	2007/04/20 10:56
L7	117	adp adj receptor	USPAT	OR	ON	2007/04/20 10:56
L8	356	adp adj receptor	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/20 11:55
L9	5157	l8 or (anti adj (platelet or clotting))	US-PGPUB; USPAT; DERWENT	OR	ŌΝ	2007/04/20 10:56
L10	944	I9 and (clopidogrel or plavix)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/20 11:31
L11	773	l10 and (solid or glioma or sarcoma or carcinoma)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/20 10:57
L12	95	l11 and (solid adj tumor)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/20 10:58
L13	2204	(clopidogrel or plavix)	US-PGPUB; USPAT; DERWENT	OR	ON.	2007/04/20 11:31
L14	276	(clopidogrel or plavix) and (lung near cancer)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/20 11:31
L15	103	l8 and (taxotere or radiosensitizing or radiation)	US-PGPบB; USPAT; DERWENT	OR	ON	2007/04/20 11:59
L16	65	I15 and (cancer or neoplasm or tumor or neoplastic or sarcoma or carcinoma)	US-PGPUB; USPAT; DERWENT	OR	ON.	2007/04/20 11:59
L17	3187	taxotere and (taxotere or radiosensitizing or radiation)	US-PGPUB; USPAT; DERWENT	OR	ÓN	2007/04/20 11:59

EAST Search History

L18	3089 63450	taxotere and (cancer or neoplasm or tumor or neoplastic or sarcoma or carcinoma) (radiation) and (cancer or neoplasm	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/20 11:59
L19	63450	(radiation) and (cancer or neonlasm				
		or tumor or neoplastic or sarcoma or carcinoma)	US-PGPUB; USPAT; DERWENT	OR	ON :	2007/04/20 11:59
L20	317165	(cancer or neoplasm or tumor or neoplastic or sarcoma or carcinoma)	US-PGPUB; USPAT; DERWENT	OR	ON .	2007/04/20 12:00
L21	10061	I19 and (solid adj tumor)	US-PGPUB; USPAT; DERWENT	OR	ΟN	2007/04/20 12:01
L22	8453	I21 and (glioma or lung)	US-PGPUB; USPAT; DERWENT	OR	ON.	2007/04/20 12:01
L23	3559	l21 and (glioma and lung)	US-PGPUB; USPAT; DERWENT	OR	ŎΝ	2007/04/20 12:01
L24	1024	l21 and (glioma and lung)	USPAT; DERWENT	OR	ÓΝ	2007/04/20 12:01
L25	1033	I23 and ((anti adj (thrombosis or thrombotic)) or adp)	US-PGPUB; USPAT; DERWENT	OR	ÓN	2007/04/20 12:02
L26	252	I23 and ((anti adj (thrombosis or thrombotic)) or adp)	USPAT; DERWENT	OR	ÓИ	2007/04/20 12:03
L27	157	I26 and (radiation adj therapy)	USPAT; DERWENT	OR	ON	2007/04/20 12:20
L28	2	"5707642".pn.	USPAT; DERWENT	OR	ON	200 7/04/ 20 12:20
L29	2	"6211171".pm	USPAT; DERWENT	OR	ON	2007/04/20 12:25
L30	2	"6384042".pn.	USPAT; DERWENT	OR	ÓИ	2007/04/20 12:46
L31	25	trigger adj point adj therapy	USPAT; DERWENT	OR	ΟN	2007/04/20 12:47
L32	2	l31 and fibromyalgia	USPAT; DERWENT	OR OR	-ON	2007/04/20 12:47

=> file reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL SESSION 0.21 0.21

FILE 'REGISTRY' ENTERED AT 10:38:17 ON 20 APR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 APR 2007 HIGHEST RN 931104-30-2 DICTIONARY FILE UPDATES: 19 APR 2007 HIGHEST RN 931104-30-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s clopidogrel

L1 13 CLOPIDOGREL

=> s clopidogrel/cn

L2 1 CLOPIDOGREL/CN

=> file caplus

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
10.35
10.56

FILE 'CAPLUS' ENTERED AT 10:38:29 ON 20 APR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Apr 2007 VOL 146 ISS 18 FILE LAST UPDATED: 19 Apr 2007 (20070419/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s 12 <> or clopidogrel?
```

SmartSELECT INITIATED

New TRANSFER and ANALYZE Commands Now Available See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS

SINCE FILE

TOTAL SESSION

FULL ESTIMATED COST

ENTRY 0.47

11.03

FILE 'REGISTRY' ENTERED AT 10:38:40 ON 20 APR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

SET SMARTSELECT ON SET COMMAND COMPLETED

SEL L2 1-

L3

SEL L2 1- CHEM :

7 TERMS

SET SMARTSELECT OFF SET COMMAND COMPLETED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY 11.65 SESSION

1 22.68

FILE 'CAPLUS' ENTERED AT 10:38:41 ON 20 APR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

S L3 OR CLOPIDOGREL?

1546 CLOPIDOGREL?

L5 1562 L4 OR CLOPIDOGREL?

=> s 15 and (solid tumor or cancer or neoplasm or carcinoma or sarcoma)

1071520 SOLID

286987 SOLIDS

1282589 SOLID

(SOLID OR SOLIDS)

405122 TUMOR

157223 TUMORS

454786 TUMOR ·

(TUMOR OR TUMORS)

12883 SOLID TUMOR

(SOLID(W) TUMOR)

312986 CANCER

45962 CANCERS

324782 CANCER

(CANCER OR CANCERS)

443852 NEOPLASM

36419 NEOPLASMS

460769 NEOPLASM

(NEOPLASM OR NEOPLASMS)

158653 CARCINOMA

32121 CARCINOMAS

164 CARCINOMATA

```
166525 CARCINOMA
                 (CARCINOMA OR CARCINOMAS OR CARCINOMATA)
         39008 SARCOMA
          4364 SARCOMAS
           102 SARCOMATA
         40678 SARCOMA
                 (SARCOMA OR SARCOMAS OR SARCOMATA)
L6
            67 L5 AND (SOLID TUMOR OR CANCER OR NEOPLASM OR CARCINOMA OR SARCOM
=> s 16 and pd <=2002
      22823143 PD <=2002
                 (PD<=20029999)
L7
            16 L6 AND PD <=2002
=> focus
PROCESSING COMPLETED FOR L7
             16 FOCUS L7 1-
=> d ibib abs hitstr 1-16
   ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
                        2002:927185 CAPLUS
DOCUMENT NUMBER:
                        138:24716
TITLE:
                        Preparation of azolecarboxylic acids useful as
                        antidiabetic and antiobesity agents
INVENTOR(S):
                        Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
PATENT ASSIGNEE(S):
                      Bristol-Myers Squibb Company, USA
                        PCT Int. Appl., 169 pp.
SOURCE:
                        CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
     PATENT NO.
                       KIND
                               DATE
                                         APPLICATION NO.
                                                                 DATE
     -----
                        ----
                                          -----
                               _____
    WO 2002096358
                        A2
                                          WO 2002-US16633
                               20021205
                                                           20020523 <--
    WO 2002096358
                        A3
                               20030327
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
            GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
            GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2449160
                        A1
                               20021205
                                         CA 2002-2449160
                                                                 20020523 <--
    EP 1390363
                         A2
                               20040225
                                         EP 2002-729306
                                                                20020523
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    TR 200400650
                        Т3
                               20040621
                                           TR 2004-650
                                                                 20020523
    HU 200401504
                         A2
                               20041129
                                          HU 2004-1504
                                                                 20020523
    JP 2004536070
                        T
                               20041202
                                          JP 2002-592871
                                                                 20020523
    TW 235061
                        В
                               20050701
                                           TW 2002-91111100
                                                                 20020524
PRIORITY APPLN. INFO.:
                                                             P 20010530
                                          US 2001-294380P
                                                             พ่ 20020523
```

WO 2002-US16633

OTHER SOURCE(S): MARPAT 138:24716

GT

R2?

$$R^{2}$$
?

 R^{2} ?

 R^{2} ?

 R^{2}
 R^{3}
 R^{3}

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, $(CH2) \times 20 (CH2) \times 3$; x = 1-5; x1 = 2-5; x2, x3 = 0-5; ≥ 1 of x2, x3 \neq 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, alkyl(halo)aryloxycarbonyl, alkoxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkyl, aminocarbonyl, substituted aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aryloxyarylalkyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylsulfinylarylcarbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor- γ (PPAR γ) and stimulators of peroxisome proliferation activated receptor- α (PPAR α). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPAR α and to PPAR γ ligand binding domains with IC50 = 69

Ι

IT 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coadministration; preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

```
ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
```

ACCESSION NUMBER:

2002:927184 CAPLUS

DOCUMENT NUMBER:

138:14048

TITLE:

Preparation of oxazolylethoxyphenylprolines and related compounds as antidiabetic and antiobesity

INVENTOR(S):

Cheng, Peter T.; Jeon, Yoon; Wang, Wei;

PATENT ASSIGNEE(S):

Bristol-Myers Squibb Company, USA

SOURCE:

PCT Int. Appl., 107 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.					KIND DATE		APPLICATION NO.					*	DATE				
	2002 2002				A2		2002	1205							2	3020	523	<
		CO, GM, LS, PL, UA, GH, KG, GR,	CR, HR, LT, PT, UG, GM, KZ, IE,	CU, HU, LU, RO, US, KE, MD, IT,	CZ, ID, LV, RU, UZ, LS, RU, LU,	DE, IL, MA, SD, VN, MW, TJ, MC,	AU, DK, IN, MD, SE, YU, MZ, TM,	DM, IS, MG, SG, ZA, SD, AT, PT,	DZ, JP, MK, SI, ZM, SL, BE, SE,	EC, KE, MN, SK, ZW SZ, CH, TR,	EE, KG, MW, SL, TZ, CY,	ES, KP, MX, TJ, UG, DE,	FI, KR, MZ, TM, ZM, DK,	GB, KZ, NO, TN, ZW, ES,	GD, LC, NZ, TR, AM, FI,	GE, LK, OM, TT, AZ, FR,	GH, LR, PH, TZ, BY, GB,	
US CA EP JP HU US PRIORIT	2005 2006 2006 Y APP	0926 556 006 433 AT, IE, 5069 0022 1895 LN.	BE, SI, 54 6 98 INFO	CH, LT,	A1 B2 A1 A2 DE, LV, T A2 A1	DK, FI,	2006 2002 2004 ES, RO, 2005 2006	0515 0912 1205 0331 FR, MK, 0310 1128 0824	GB, CY,	US 2 CA 2 CEP 2 CE	002-2 002-2 TR 002-2 006-2 006-2	24490 73719 LI, 59287 226 40679 29450 15334	006 92 LU, 70 99	NL,	20 SE, 20 20 20 20 20 23	00205 MC, 00205	523 523 PT, 523 523 119 530	
OTHER SO	HER SOURCE(S):				MARI	TA?	138:	14048	3									

$$R^{2}$$
?
 R^{2} ?
 R^{2} ?
 R^{2} ?
 R^{2}
 R^{2}

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, with an alkenyl or alkynyl bond in the chain, $(CH2) \times 20(CH2) \times 3$; x = 1-5; x1 = 2-5; x2, x3 = 0-5; provided that ≥ 1 of x2 and $x3 \neq 0$; X1 = CH, N; X2 = C, N, O, S; X3 = C, N; X4 = C, N, O, S provided that ≥ 1 of X2, X3, X4 = N; in each of X1-X4, C may include CH; R1 = H, alk $\frac{1}{y}$ 1; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, aryloxyheteroarylalkyl, heteroarylalkyloxyarylalkyl, arylarylalkyl, arylalkenylarylalkyl, arylaminoarylalkyl, etc.; Y = CO2R4, 1-tetrazolyl, P(0) (OR4a)R5, P(0) (OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; Z = (CH2)x4, (CH2)x5, (CH2)x6O(CH2)x7; x4 = 1-5; x5 = 2-5; x6, x7 = 0-4], were prepared as antidiabetic and antiobesity agents (no data). Thus, the title compound (II) was prepared in 6 steps. IΤ 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

I

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS, on STN

ACCESSION NUMBER: 2002:540258 CAPLUS

DOCUMENT NUMBER: 137:109267

TITLE: Preparation of benzoxepinopyridines as HMG-CoA

reductase inhibitors

INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing

PATENT ASSIGNEE(S): US

SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S.

Ser. No. 875,155.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
US 2002094977 US 6627636	A1 B2	20020718	US 2001-7407	!	20011204 <	-
US 2002013334 PRIORITY APPLN. INFO.:	A1	20020131	US 2001-875155 US 2000-211595P	P	20010606 < 20000615	-
OTHER SOURCE(S):	MARPAT	137:109267	US 2001-875155	A2 I	20010606	

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = 0, S, SO, SO2, NR7; Z = HOCHCH2CH(OH)CH2CO2R3, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H, alkyl, metal ion; R4 = H, halo, CF3, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and atherosclerosis (no data). A multistep synthesis of II is reported.

IT 113665-84-2, Clopidogrel


RL: PAC (Pharmacological activity); THU (Therapeutic use); |BIOL (Biological study); USES (Uses)

(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L8 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:392331 CAPLUS

DOCUMENT NUMBER: 140:406798

TITLE: Preparation of benzoxepinopyridines as HMG-CoA

reductase inhibitors

INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S.

Ser. No. 875,155, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	PPLICATION NO.				
US 2004092573 US 6812345	A1 B2	20040513	US 2003-602752	+	20030624			
US 2002013334 PRIORITY APPLN. INFO.:	A1	20020131	US 2001-875155 US 2000-211595P	; • P	20010606 < 20000615			
OTHER SOURCE(S):	MARPAT	140:406798	US 2001-875155	B2	20010606			

OTHER SOURCE(S): MARPAT 140:406/98

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO2, NR7; Z = HOCHCH2CH(OH)CH2CO2R3, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H, alkyl, metal ion; R4 = H, halo, CF3, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

IT 113665-84-2, Clopidogrel


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2002:487403 CAPLUS

DOCUMENT NUMBER:

137:47218

TITLE:

Preparation of thieno[2,3-d]pyrimidine derivatives as

phosphodiesterase V inhibitors and their

pharmaceutical formulations containing antithrombotic, calcium antagonist, prostaglandin or prostaglandin

derivative medicaments.

INVENTOR(S):

Eggenweiler, Hans-Michael; Eiermann, Volker

Merck Patent Gmbh, Germany PCT Int. Appl., 96 pp. PATENT ASSIGNEE(S):

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	TENT	NO.			KIND DATE			APPLICATION NO.			DATE							
	2002		50		A2		2002	0627		WO 2	001-	EP13	915		2	0011	128 <	
	W:	ΑE,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	co,	CR,	
		CU,	CZ,	DE,	DK,	DM,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	
		ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	
		LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	NO,	NZ,	PH,	PL,	PT,	RO,	RU,	SD,	
							ТJ,											
		ZA,	ZW													-	·	
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	CH,	
		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
		BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
DE	1006	3223			A1		2002	0620		DE 20	000-	1006	3223		2	0001	219 <	
DE	1006	3885			A1		2002	0711		DE 20	000-	1006	3885		2	0001	221 <	
DE	1006	4992			A1		2002	0627		DE 20	000-	1006	4992		2	0001	219 < 221 < 223 < 128 < 128 <	
CA	2431	074			A1		2002	0627	(CA 20	001-	2431	074		2	0011	128 <	
AU	2002	2795	7		A		2002	0701	2	AU 20	002-	2795	7		2	0011	128 <	
EP	1347	761			A2		2003	1001	,	EP 20	001-	9895:	33		2	0011	128	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,		RO,											
BR	2001	0162	55		A		2003								2			
HU	2003	0328	9		A2		2004	0128		HU 20	003-3	3289			2	0011	128	
JP	2004	5162	69		${f T}$		2004	0603		JP 20	002-	55099	90		2	0011:	128	
NO	2004 2003 2004	0027	72		Α		2003	0618	1	NO 20	003-2	2772			2	0030	618	
US	2004	0728	46		A1		2004	0415	ı	JS 20	003-4	4511:	18		2	0030	619	
	2003				Α		2005	0311	•	IN 20	003-1	KN899	9					
PRIORIT	Y APP	LN.	INFO	. :					1	DE .20	000-1	10063	3223	i	A 20			
													3885		A 20			
								•					1992		A 20			
													915		W 20	0011:	128	
OTHER S	OURCE	(S):			CASE	REAC	т 13	7:472	218;	MARI	PAT :	137:4	47218	3				

R1
$$R^2$$
 $N + CH_2$ R^3 R^4 $R^$

0

AΒ This invention discloses the preparation of title compds. I and their pharmaceutically acceptable salts and solvates [wherein: R1, R2 independently = H, A, halogen, with the proviso that one of R1 or R2 always \neq H; or R1R2 = C3-5 alkylene; R3, R4 = H, A, OA, OH, halogen; or R3R4 = C3-5 alkylene, OCH2CH2, OCH2O, OCH2CH2O; X = C1-10 linear or branched alkyl with 1-2 optional CH:CH in lieu of CH2, C6H4(CH2)m, cycloalkylalkyl; R = CO2H, CO2A, CONH2, CONHA, CONA2, CN; A = alkyl; m = 1 or 2; n = 0-3]. For example, condensation of 4-chloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine-2-propanoic acid Me ester and 3-chloro-4-methoxybenzylamine provided claimed thieno[2,3-d]pyrimidine-2-propanoate II as an oil. Pharmaceutical formulations containing I (as phosphodiesterase V inhibitors) in combination with an antithrombotic, calcium antagonist, prostaglandin or prostaglandin derivative are claimed for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure, chronic obstructive pulmonary disease (COPD), pulmonary heart disease, right ventricular failure, arteriosclerosis, permeability conditions of reduced cardiovascular patency, peripheral vascular illnesses, cerebral apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumors, kidney failure, cirrhosis of the liver and for treating female sexual dysfunction (no data provided).

II

IT 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical formulations with; preparation of benzothieno[2,3-d]pyrimidine derivs. for use in pharmaceutical formulations with antithrombotic, calcium antagonist, prostaglandin or prostaglandin derivative medicaments)

RN 113665-84-2 CAPLUS

CN

Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)|-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2002:487402 CAPLUS 137:47217

TITLE:

Preparation of benzothieno[2,3-d]pyrimidine

derivatives as phosphodiesterase V inhibitors and

their pharmaceutical formulations containing

antithrombotic, calcium antagonist, prostaglandin or

prostaglandin derivative medicaments.

Eggenweiler, Hans-Michael; Eiermann, Volker

PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany

SOURCE:

INVENTOR(S):

PCT Int. Appl., 85 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	TENT I	NO.			KIN		DATE				ICAT				D.	ATE		
	2002				A2		2002								2	0011	128	<
	W:	AE, CO, GM, LS, PT,	AG, CR, HR, LT, RO,	AL, CU, HU, LU, RU,	AM, CZ, ID, LV, SD,	AT, DE, IL, MA, SE,	AU, DK, IN, MD, SG,	AZ, DM, IS, MG,	BA, DZ, JP, MK,	EC, KE, MN,	EE, KG, MW,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NO,	GD, LC, NZ,	GE, LK, PH,	GH, LR, PL,	
	RW:	GH, CY,	GM, DE,	KE, DK,	ES,	MW, FI,	MZ, FR, CM,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
DE	1006						2002											<
ĎΕ	1006	3884			A1		2002	0627	1	DE 2	000-	1006	3884	:	2	0001	221	<
DE	1006	4991			A1		2002	0627		DE 2	000-	1006	4991		2	0001	223	<
CA	24313 20023	147			A1		2002	0627	(CA 2	001-	2431	147		2	0011	128	<
AU	2002	2636:	2		Α		2002	0701	i	AU 2	002-	2636	2		2	0011	128	<
EP	1347	762			A2		2003	1001]	EP 2	001-	9956	77		2	0011	128	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR							
BR	20010 20045 20030	0162	47		Α		2003	1104	1	BR 2	001-	1624	7		2	0011	128	
JP	20045	5162	68		T		2004	0603		JP 2	002-	5509	89	ı	2	0011	128	
NO	20030	0027	71		A		2003	0618	Ì	NO 2	003-	2771			2	0030	618	
US	20040	0589	40		A1		2004	0325	I	US 2	003-	4510	25		2	0030	619	
IN	20031	KNOO	898		Α		2005	0311		IN 2	003-	KN89	8		2	0030	714	
PRIORIT	Y APP	LN.	INFO	.:					1	DE 2	000-	1006	3221	i	A 2	0001	219	
									1	DE 2	000-	1006	3884	Ž	A 2	0001	221	
											000-					0001	223	
									1	WO 2	001-	EP13	913	1	W 2	0011	128	
OTHER SO	OURCE	(S):			CASI	REAC	T 13	7:472	217:	MAR	PAT	137:	4721	7				

OTHER SOURCE(S):

CASREACT 137:47217; MARPAT 137:47217

$$\begin{array}{c|c}
H & N-CH_2 & R^1 \\
N & R^2 & R^2
\end{array}$$

AΒ This invention discloses the preparation of title compds. I and their pharmaceutically acceptable salts and solvates [wherein: R1, R2 = H, A, OA, OH, halogen; or R1R2 = C3-5 alkylene, OCH2CH2, CH2OCH2, OCH2O, OCH2CH2O; X = Ph, benzyl, cycloalkyl, cycloalkylalkyl, C1-10 linear or branched alkyl with 1-2 optional CH:CH in lieu of CH2; A = alkyl; R =CO2H, CO2A, CONH2, CONHA, CONA2, CN]. For example, condensation of 4-(4-chloro[1]benzothieno[2,3-d]pyrimidin-2-yl)benzoic acid Me ester and 3-chloro-4-methoxybenzylamine provided claimed [1]benzothieno[2,3d]pyrimidin-2-ylbenzoate II (mp. 203-204°). Pharmaceutical formulations containing I (as phosphodiesterase V inhibitors) in combination with an antithrombotic, calcium antagonist, prostaglandin or prostaglandin derivative are claimed for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure, chronic obstructive pulmonary disease (COPD), pulmonary heart disease, right ventricular failure, arteriosclerosis, permeability conditions of reduced cardiovascular patency, peripheral vascular illnesses, cerebral apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumors, kidney failure, cirrhosis of the liver and for treating female sexual dysfunction (no data provided).

II

IT 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical formulations with; preparation of benzothieno[2,3-d]pyrimidine derivs. for use in pharmaceutical formulations with antithrombotic, calcium antagonist, prostaglandin or prostaglandin derivative medicaments)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:487404 CAPLUS

DOCUMENT NUMBER: 137:47219

TITLE: Preparation of pyrazolo[4,3-d]pyrimidine derivatives

as phosphodiesterase V inhibitors and their

pharmaceutical formulations containing antithrombotic, calcium antagonist, prostaglandin or prostaglandin

i

derivative medicaments.

INVENTOR(S): Eggenweiler, Hans-Michael; Eiermann, Volker

PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PA'	TENT NO.		KIND	DATE	APPLICATION NO.	
WO.	W: AE, A CZ, I IL, I	AL, AM, DE, DK, IN, IS,	AT, AU, DM, EC, JP, KE,	, AZ, BA, , EE, ES, , KG, KP,	WO 2001-EP13916 BB, BG, BR, BY, CA, FI, GB, GD, GE, GH, KR, KZ, LC, LK, LR,	20011128 < CH, CN, CR, CU, GM, HR, HU, ID, LS, LT, LU, LV,
	SG, S RW: GH, C CY, I	SI, SK, GM, KE, DE, DK,	SL, TJ, LS, MW, ES, FI,	, TM, TR, , MZ, SD, , FR, GB,	NO, NZ, PH, PL, PT, TT, TZ, UA, UG, US, SL, SZ, TZ, UG, ZM, GR, IE, IT, LU, MC, GN, GQ, GW, ML, MR,	UZ, VN, YU, ZA, ZW ZW, AT, BE, CH, NL, PT, SE, TR,
DE	10063224				DE 2000-10063224	
DE	10063882		A1	20020711	DE 2000-10063882	20001221 <
DE	10064993		A1	20020704	DE 2000-10064993	20001223 <
CA	2431077		A1	20020627	CA 2001-2431077 AU 2002-29573	20011128 <
AU	200229573		Α	20020701	AU 2002-29573	20011128 <
	1343506		A1	20030917	EP 2001-990452	20011128
					GB, GR, IT, LI, LU,	NL, SE, MC, PT,
					CY, AL, TR	
BR	2001015999	5	A	20040113	BR 2001-15995	20011128
ни	200303315		A2	20040128	HU 2003-3315	20011128
JP	2004516270	0	T	20040603	JP 2002-550991	20011128
NO	2003002773	3	A	20030618	BR 2001-15995 HU 2003-3315 JP 2002-550991 NO 2003-2773 US 2003-451105 IN 2003-KN905	20030618
US	2004063730	0	A1	20040401	US 2003-451105	20030619
IN	2003KN0090	05	. A	20050311	IN 2003-KN905	20030715
PRIORIT	Y APPLN. IN	NFO.:			DE 2000-10063224	A 20001219
					DE 2000-10063882	A 20001221
					DE 2000-10064993	A 20001223
					WO 2001-EP13916	W 20011128
OTHED CO	MDCE/CL.		MADDAM	127.4701	٦	

OTHER SOURCE(S): MARPAT 137:47219

AB This invention discloses the preparation of title compds. I and their pharmaceutically acceptable salts and solvates [wherein: R1, R2 independently = H, A, OH, OA, halogen; or R1R2 = C3-5 alkylene, OCH2CH2, CH2OCH2, OCH2O, OCH2CH2O; R3, R4 independently = H, A; X = cycloalkyl, cycloalkylalkyl, Ph, benzyl, C1-10 linear or branched alkyl with 1-2 optional CH:CH in lieu of CH2, or optionally interrupted by O, S, or SO; R = CO2H, CO2A, CONH2, CONHA, CONA2, CN; A = alkyl]. For example, condensation of 3-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]propionic acid Me ester and 3-chloro-4-methoxybenzylamine provided claimed pyrazolo[4,3-d]pyrimidin-5-ylpropanoate II as an oil. Pharmaceutical formulations containing I (as phosphodiesterase V inhibitors) in combination with an antithrombotic, calcium antagonist, prostaglandin or prostaglandin derivative medicament are claimed for the treatment of angina, hypertension, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, right ventricular failure, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, cerebrovascular accident, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumors, kidney failure, cirrhosis of the liver, and female sexual dysfunctions (no data provided).

IT 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical formulations with; preparation of benzothieno[2,3-d]pyrimidine derivs. for use in pharmaceutical formulations with antithrombotic, calcium antagonist, prostaglandin or prostaglandin derivative medicaments)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:151052 CAPLUS

DOCUMENT NUMBER: 146:244343

TITLE: Peptides and peptide mimetics to treat pathologies

characterized by an inflammatory response

INVENTOR(S): Fogelman, Alan M.; Navab, Mohamad

PATENT ASSIGNEE(S): The Regents of the University of California, USA SOURCE: U.S. Pat. Appl. Publ., 313pp., Cont.-in-part of U.S.

Ser. No. 423,830.

CODEN: USXXCO

DOCUMENT TYPE: LANGUAGE: Patent English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	1	DATE
US 2007032430 US 6664230 US 2003045460	A1 B1 A1	20070208 20031216 20030306	US 2006-407390 US 2000-645454 US 2001-896841	· :	20060418 20000824 20010629
US 6933279 CN 1375299 CN 1739787 CN 1911439 CN 1931358 CN 1931359 CN 1943781	B2 A A A A A	20050823 20021023 20060301 20070214 20070321 20070321 20070411	CN 2001-103876 CN 2005-10103876 CN 2006-10100670 CN 2006-10100667 CN 2006-10100669 CN 2006-10100668	;	20010823 < 20010823 20010823 20010823 20010823 20010823
US 2003171277 US 7144862 US 2003229015 US 7166578 US 2004266671 US 7199102	A1 B2 A1 B2 A1 B2	20030911 20061205 20031211 20070123 20041230 20070403	US 2002-187215 US 2002-273386 US 2003-423830	1	20020628 20021016 20030425
JP 2006056899 JP 2006312650 PRIORITY APPLN. INFO.:	A A	20060302 20061116	JP 2005-304531 JP 2006-220831 US 2000-645454 US 2001-896841 US 2002-187215 US 2002-273386 US 2003-423830 US 2005-676431P	A2 A2 A2 A2 P	20051019 20060814 20000824 20010629 20020628 20021016 20030425 20050429
OWIED COURGE (G)	MIDDIG	146 044242	US 2005-697495P CN 2001-103876 CN 2001-817280 CN 2005-10103876 JP 2002-520844 WO 2001-US26497 JP 2005-304531	A3 A3 A3 A2	20050707 20010823 20010823 20010823 20010823 20010823 20051019

OTHER SOURCE(S): MARPAT 146:244343

AB The invention provides novel active agents (e.g. peptides, small organic mols., amino acid pairs, etc.) that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiments, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route. Peptide preparation is included.

IT 113665-84-2, Clopidogrel

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptidic compds. to treat diseases characterized by inflammatory response)

RN 113665-84-2 CAPLUS

Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:462399 CAPLUS

DOCUMENT NUMBER: 137:47209

TITLE: Preparation of thieno[2,3-d]pyrimidine derivatives as

phosphodiesterase V inhibitors and their

pharmaceutical formulations containing antithrombotic

medicaments.

INVENTOR(S): Eggenweiler, Hans-Michael; Eiermann, Volker

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Ger. Offen., 30 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PA.	TENT	NO.			KIN	D	DATE				ICAT					ATE		
CA WO	2431	074 0496	50		A1 A1 A2		2002 2002	0627 0627	1	DE 2 CA 2	000- 001-	1006 2431	3223 074		2	0011	219 <- 128 <- 128 <-	
***	W:	AE, CU, ID, LV, SE,	AL, CZ, IL, MA,	AM, DE, IN, MD, SI,	AT, DK, IS, MG,	AU, DM, JP, MK,	AZ, EC, KE, MN,	BA, EE, KG, MW,	BB, ES, KP, MX,	FI, KR, NO,	BR, GB, KZ, NZ, TZ,	GD, LC, PH,	GE, LK, PL,	GH, LR, PT,	GM, LS, RO,	HR, LT, RU,	HU, LU, SD,	
		GH, CY, BF,	GM, DE, BJ,	KE, DK, CF,	ES, CG,	FI, CI,	FR, CM,	GB, GA,	GR, GN,	IE, GQ,	GW,	LU, ML,	MC, MR,	NL, NE,	PT, SN,	SE, TD,	TR, TG	
AU	1347	2795 761	7		A		2002	0701	i	AU 2	002-	2795	7		20	0011	128 <-	
£F	B.	ΔT	BE	CH	DF.	DK	2003 FS	EB TOOT	GB .	CP Z	IT,	9093. TT	33 111	NIT	21 CE	MC.	L∠8 DT	
BR																		
HU	2003	0328	9		A2		2004	0128	j	HU 2	003-	3289			20	0011	128	
JP	2004	5162	69		T		2004	0603		JP 2	002-	5509	90		20	0011	128	
NO	2003	0027	72		Α		2003	0618	1	NO 2	003-	2772			20	0030	518	
US	IE, SI, LT BR 2001016255 HU 200303289 JP 2004516269 NO 2003002772 US 2004072846						2004	0415	Į	JS 2	003-	4511:	18		20	0030	519	
IN	US 2004072846 IN 2003KN00899						2005	0311		IN 2	003-1	KN899	9		20	0030	714	
ZA	ZA 2003005537 RIORITY APPLN. INFO.:						2004	1018		ZA 2	003-	5537			20	0030	717	
PRIORITI	C APP.	LIV.	TNFO	. :							000-							
											000-1				A 20			
`											000 001-i				A 20 V 20	0011		
OTHER SO	HER SOURCE(S):						т 13	7:472	209:	MAR	PAT 1	37.4	1720°	a jv	v 20	.011	40	

OTHER SOURCE(S): CASREACT 137:47209; MARPAT 137:47209

R1
$$R^2$$
 R^3 R^3 R^4 R

AB This invention discloses the preparation of title compds. I and their pharmaceutically acceptable salts and solvates [wherein: R1, R2 independently = H, A, halogen, with the proviso that one of R1 or R2 always \neq H; R1R2 = C3-5 alkylene; R3, R4 = H, A, OA, OH, halogen; R3R4 = C3-5 alkylene, OCH2CH2, OCH2O, OCH2CH2O; X = C1-10 linear or branched alkyl with 1-2 optional CH:CH in lieu of CH2, C6H4(CH2)m, cycloalkylalkyl; R = CO2H, CO2A, CONH2, CONHA, CONA2, CN; A = alkyl; m = 1 or 2; n = 0-3]. For example, condensation of 4-chloro-5,6,7,8tetrahydro[1]benzothieno[2,3-d]pyrimidine-2-propanoic acid Me ester and 3-chloro-4-methoxybenzylamine provided claimed thieno[2,3-d]pyrimidine-2propanoate II as an oil. Pharmaceutical formulations containing I (as phosphodiesterase V inhibitors) in combination with an antithrombotic medicament are claimed for the treatment of angina, (pulmonary) hypertension, congestive heart failure, arteriosclerosis, peripheral vascular diseases, stroke, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumors, kidney insufficiency, liver cirrhosis, and female sexual dysfunction (no data provided).

IT 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical formulations with; preparation of thieno[2,3-d]pyrimidine derivs. for use in pharmaceutical formulations with antithrombotics)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl),-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8

2002:462398 CAPLUS ACCESSION NUMBER:

137:33315 DOCUMENT NUMBER:

Preparation of [1]benzothieno[2,3-d]pyrimidine TITLE: derivatives as phosphodiesterase V inhibitors and

their pharmaceutical formulations containing

antithrombotic medicaments.
Eggenweiler, Hans-Michael; Eiermann, Volker INVENTOR(S):

Merck Patent GmbH, Germany PATENT ASSIGNEE(S): SOURCE:

Ger. Offen., 26 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	TENT					D DATE	:			ICAT:					ATE		
DE CA WO	1006 2431 2002	3221 147 0496	49		A1 A1 A2	2002 2002 2002	0627 0627	- (DE 20	000-: 001-:	1006: 2431:	3221 147		20	0011		_
WO		AE, CO, GM, LS, PT,	AG, CR, HR, LT, RO,	AL, CU, HU, LU, RU,	AM, CZ, ID, LV, SD,	2002 AT, AU, DE, DK, IL, IN, MA, MD, SE, SG, ZA, ZW	AZ, DM, IS, MG,	BA, DZ, JP, MK,	EC, KE, MN,	EE, KG, MW,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NO,	GD, LC, NZ,	GE, LK, PH,	GH, LR, PL,	
		GH, CY, BF,	GM, DE, BJ,	KE, DK, CF,	LS, ES, CG,	MW, MZ, FI, FR, CI, CM,	GB, GA,	GR, GN,	IE, GQ,	IT, GW,	LU, ML,	MC, MR,	NL, NE,	PT, SN,	SE, TD,	TR, TG	
AU	2002	2636	2		Α	2002	0701	7	AU 20	002-	2636	2		20	0011	L28 <	-
EP						2003											
	R:					DK, ES,					LI,	LU,	NL,	SE,	MC,	PT,	
	0001					FI, RO,						_					
BK	2001	0162	4 /		A	2003	1104	i	BR 21	001-	1624	<i>/</i>		20	0011.	128	
JP NO	2004	0027	ნგ 21		T	2004 2003	0610	,	JP 21	JUZ-:	5509i	39		21	JUII.	L28	
NO IIS	2003	0027 0589	/ T		Α Δ1	2003	0325		10 21	103- <i>i</i>	4	25		21	7020i	510 510	
TN	2003	KNUU	898 898		Α	2005	0323		TN 21	303 303-1	KNBO	2.0		20	1030'	714	
ZA	2003	0055	48		A	2004	1117		ZA 21	003-!	5548	,	1	20	00301	717	
PRIORIT						200.						3221			00012		
								1	DE 20	000-i	1006	3884 4991	įz	A 20	00012	221	
												913			0011		
OTHER SO	OURCE	(S):			CAS	REACT 13	7:33							. 21		. 2 0	

$$H$$
 $N-CH_2$
 R^2
 R^2

ΙΙ

AB This invention discloses the preparation of title compds. I and their pharmaceutically acceptable salts and solvates [wherein: R1, R2 = H, A, OA, OH, halogen; R1R2 = C3-5 alkylene, OCH2CH2, CH2OCH2, OCH2O, OCH2CH2O; X = Ph, benzyl, cycloalkyl, cycloalkylalkyl, C1-10 linear or branched alkyl with 1-2 optional CH:CH in lieu of CH2; A = alkyl; R = CO2H, CO2A, CONH2, CONHA, CONA2, CN]. For example, condensation of 4-(4-chloro[1]benzothieno[2,3-d]pyrimidin-2-yl)benzoic acid Me ester and 3-chloro-4-methoxybenzylamine provided claimed [1]benzothieno[2,3d]pyrimidin-2-ylbenzoate II (mp. 203-204°). Pharmaceutical formulations containing I (as phosphodiesterase V inhibitors) in combination with an antithrombotic medicament are claimed for the treatment of angina, (pulmonary) hypertension, congestive heart failure, arteriosclerosis, peripheral vascular diseases, stroke, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumor, kidney insufficiency, liver cirrhosis, and female sexual dysfunction (no data provided).

IT 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical formulations with; preparation of [1]benzothieno[2,3-d]pyrimidine derivs. for use in pharmaceutical formulations with antithrombotics)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2002:813926 CAPLUS

DOCUMENT NUMBER: 137:304829

TITLE: Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)]]]

amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-

yl]methyl]-N,3,3-trimethylbutanamide Hughes, David E.; Seidenberg, Beth C.

INVENTOR(S): Hughes, David E.; Seidenberg, Beth C. PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 24 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

P	ATENT	NO.			KIN	D	DATE		i	APPL	ICAŢ	ION	NO.	. !	D	ATE		
W	2002	 0831	30		A1	-	2002	1024	1	WO 2	002-	US11	992		2	0020	 412 <	_
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	NZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,	
		UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	zw								
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	CH,	
		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
		BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
ΙA	J 2002	2546	31		A1		2002	1028	i	AU 2	002-	2546	31	į.	20	0204	412 <	-
US	3 2003	0405	34		A1		2003	0227	1	US 2	002-	1215	20		20	00204	112	
PRIORI	. :					į	US 2	001-	2840	80P]	P 20	010	116				
									1	WO 2	002-	US11	992	- 7	N 20	00204	112	

Endothelin antagonist N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino] sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide surprisingly exists as separable enantiomeric atropisomers. The (+)-dextrorotatory atropisomer demonstrates remarkably higher potency than either the (-)-levorotatory atropisomer or the racemate. The (+)-dextrorotatory atropisomer is suitable for treatment of endothelin-related disorders, such as hypertension, renal diseases, atherosclerosis, restenosis, congestive heart failure, diabetic nephropathy, cancer, asthma, etc., alone or in combination with, e.g., angiotensin, renin, or ACE inhibitors, diuretics, cardiac glycosides, antiplatelet agents, etc.

IT 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT:

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

1

2002:462400 CAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 137:47210

TITLE: Preparation of pyrazolo[4,3-d]pyrimidine derivatives

as phosphodiesterase V inhibitors and their

pharmaceutical formulations containing antithrombotic

medicaments.

Eggenweiler, Hans-Michael; Eiermann, Volker Merck Patent GmbH, Germany INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE: Ger. Offen., 28 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	TENT N	o. 			KIN		DATE								D.	ATE		
CA	10063 24310 20020	77			A1 A1		2002	0627		DE 2 CA 2	001-	1006: 2431:	3224 077		2	0011	128 <	
	RW:	CZ, IL, MA, SG, GH, CY,	DE, IN, MD, SI, GM, DE,	DK, IS, MG, SK, KE, DK,	DM, JP, MK, SL, LS, ES,	EC, KE, MN, TJ, MW, FI,	EE, KG, MW, TM, MZ, FR,	ES, KP, MX, TR, SD, GB,	FI, KR, NO, TT, SL, GR,	GB, KZ, NZ, TZ, SZ, IE,	GD, LC, PH, UA, TZ, IT,	GE, LK, PL, UG, UG, LU,	GH, LR, PT, US, ZM, MC,	GM, LS, RO, UZ, ZW, NL,	HR, LT, RU, VN, AT, PT,	HU, LU, SD, YU, BE, SE,	TR,	,
711	20022																TG	
	13435																	
L-1	R: 1																	
		7°	CT.	TT	TV	DI,	PO	ME,	GD,	DI,	TI,	LI,	TO,	NL,	SE,	MC,	P1,	
BR	20010	1500	15	ш.,	ъ,	r + /	2004	0113	C1,	ישם,	001_	15001	=	1	2	0011	120	
HU	20030	3315	, J		A2		2004	0113		111 2	001-	1333. 3315	,		2	0011	120	
JP	20045	1627	, '0		T		2004	0603		TP 2	003-	5519	a 1		2	0011	120	
NO	20010 20030 20045 20030	0277	3		Ā		2003	0618	ì	NO 2	002 .	2202. 2773	71		2	0030	120 118	
US	20040	6373	30		A1		2004	0401	į	JS 2	003-	45110	0.5		2	0030	519	
IN	2003KI		A															
ZA	IN 2003KN00905 ZA 2003005542						2004	1117	:	ZA 2	003-	5542	-	1	2	0030	717	
PRIORITY	Y APPLI	. :												00012				
									I	DE 2	000-	10063	3882	1	A 2	00012	221	
									1	DE 2	000-	10064	1993	17	A 2	00012	223	
													916	1		0011		
OTHER SO	THER SOURCE(S):						т 13	7:472	210;	MAR	PAT :	137:4	17210) '				

AB This invention discloses the preparation of title compds. I and their pharmaceutically acceptable salts and solvates [wherein: R1, R2 independently = H, A, OH, OA, halogen; R1R2 = C3-5 alkylene, OCH2CH2, CH2OCH2, OCH2O, OCH2CH2O; R3, R4 independently = H, A; X = cycloalkyl, cycloalkylalkyl, Ph, benzyl, C1-10 linear or branched alkyl with 1-2 optional CH:CH in lieu of CH2, or optionally interrupted by O, S, or SO; R = CO2H, CO2A, CONH2, CONHA, CONA2, CN; A = alkyl]. For example, condensation of 3-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]propionic acid Me ester and 3-chloro-4-methoxybenzylamine provided claimed pyrazolo[4,3-d]pyrimidin-5-ylpropanoate II as an oil. Pharmaceutical formulations containing I (as phosphodiesterase V inhibitors) in combination with an antithrombotic medicament are claimed for the treatment of angina, (pulmonary) hypertension, congestive heart failure, arteriosclerosis, peripheral vascular diseases, stroke, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumor, kidney insufficiency, liver cirrhosis, and female sexual dysfunction (no data provided).

IT 113665-84-2, Clopidogrel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical formulations with; preparation of pyrazolo[4,3-d]pyrimidine derivs. for use in pharmaceutical formulations with antithrombotics)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:598215 CAPLUS

DOCUMENT NUMBER: 135:191313

TITLE: Polymorphisms in the human CYP2B6 gene and their use

in diagnostic and therapeutic applications

Zanger, Ulrich M.; Lang, Thomas

PATENT ASSIGNEE(S): Epidauros Biotechnologie A.-G., Germany

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

INVENTOR(S):

PAT	rent i	NO.			KIN	D	DATE			APPL	ICAT:	ION	NO.		D	ATE		
WO	2001 2001 2001	0591	52		A9			8080	1	WO 2	001-	EP14	56 .		2	0010	209 ·	<
WO		AE, CR, HU, LU,	AG, CU, ID, LV,	AL, CZ, IL, MA,	AM, DE, IN, MD,	AT, DK, IS, MG,	AU, DM, JP, MK,	AZ, DZ, KE, MN,	EE, KG, MW,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NO,	GD, LC, NZ,	BZ, GE, LK, PL, UG,	GH, LR, PT,	GM, LS, RO,	HR, LT, RU,	
EP	1272	GH, DE, BJ, 663	GM, DK, CF,	KE, ES, CG,	FI, CI, A2	MW, FR, CM,	MZ, GB, GA, 2003	SD, GR, GN, 0108	SL, IE, GW,	SZ, IT, ML; EP 2	TZ, LU, MR, 001-	UG, MC, NE, 9138	ZW, NL, SN, O9	AT, PT, TD,	SE, TG	TR,	BF, 209	
US PRIORITY	20042	IE, 2243	SI, 13	LT,	LV,	FI,	RO,	MK,	CY,	AL, US 20 EP 20	TR	9586: 1027:	35 01	7	20 A 20	MC, 00202 00002	202 209	

AB Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clin. characteristics with several forms of inherited abnormal expression and/or function of the CYP2B6 genes encoding cytochrome P 450 2B6. In particular, polynucleotides of mol. variant CYP2B6 genes which, for example, are associated with insufficient metabolization and/or sensitivity of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP2B6 proteins are described. In addition, variant CYP2B6

proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP2B6 gene as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compns. useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP2B6 gene product are described as well.

IT 113665-84-2, Clopidogrel

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications, human cytochrome P 450 2B6 inhibitor)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:77981 CAPLUS

DOCUMENT NUMBER: 142:162662

TITLE: Nanoparticulate glipizide compositions

INVENTOR(S): Bosch, H. William; Ryde, Niels P.

PATENT ASSIGNEE(S): Elan Pharma International Limited, USA

SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S.

Ser. No. 276,400. CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English 18

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PA'	TENT	NO.			KIN		DATE				ICAT					ATE		
US WO	2005 2002 2001 2001	0126 0872	75 64		A1 A1 A2		2001	0131 1122	,	US 2 US 1		7010 3376	64 75	ì	1	9990	622	
	W:	AE, CO, GM, LS, RO, UZ, GH, DE,	AG, CR, HR, LT, RU, VN, GM, DK,	AL, CU, HU, LU, SD, YU, KE, ES,	AM, CZ, ID, LV, SE, ZA, LS, FI,	AT, DE, IL, MA, SG, ZW MW, FR,	AU, DK, IN, MD, SI, MZ, GB,	AZ, DM, IS, MG, SK, SD, GR,	BA, DZ, JP, MK, SL, SL, IE,	EC, KE, MN, TJ, SZ, IT,	EE, KG, MW, TM,	ES, KP, MX, TR, UG, MC,	FI, KR, MZ, TT, ZW, NL,	GB, KZ, NO, TZ, AT, PT,	GD, LC, NZ, UA, BE, SE,	GE, LK, PL, UG,	GH, LR, PT, US,	
US PRIORITY	2004 Y APP	0136	13		A1			0122	 	US 2 US 1 US 1 WO 2 US 2	003-	27646 1643 3376 US15 2764	00 51 75 983	1 2 1	20 B2 19 A2 19 W 20 A2 20	9981 9990 0010 0030	001 622 518 115	
AR The	nre	sent	inv	enti.	on i	s di	rect	ad to										

The present invention is directed to nanoparticulate compns. comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of $<2 \mu$. Thus, a formulation contained spray-dried glipizide 5.33, mannitol 13.47, xylitol 40.53, citric acid 19.60, sodium bicarbonate 19.33, Asparatme 0.28, PEG-4000 0.93, and sodium stearyl fumarate 0.53%.

IT 113665-84-2, Clopidogrel

> RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nanoparticulate glipizide compns.)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7dihydro-, methyl ester, (αS) - (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:907166 CAPLUS

DOCUMENT NUMBER: 138:322

TITLE: Plasma glucosylceramide deficiency as risk factor for

thrombosis and modulator of anticoagulant protein C

INVENTOR(S): Griffin, John H.; Deguchi, Hiroshi; Fernandez, Jose

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 32 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PA'	TENT	NO.		•	KIN	D	DATE				ICAT				D.	ATE	•	
		2002 6756						2002				002-				2	0020	228	<
	WO	2002 2002	1023	25		A2		2002	1227	1	WO 2	002-	US63	40		2	0020	228 -	<
		W:	CO, GM, LS,	CR, HR, LT,	CU, HU, LU,	CZ, ID, LV,	DE, IL, MA,	AU, DK, IN, MD, SE,	DM, IS, MG,	DZ, JP, MK,	EC, KE, MN,	EE, KG, MW,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NO,	GD, LC, NZ,	GE, LK, OM,	GH, LR, PH,	
		RW:	UA, GH, KG, GR,	UG, GM, KZ, IE,	UZ, KE, MD, IT,	VN, LS, RU, LU,	YU, MW, TJ, MC,	ZA, MZ, TM, NL,	ZM, SD, AT, PT,	ZW SL, BE, SE,	SZ, CH, TR,	TZ, CY,	UG, DE,	ZM, DK,	ZW,	AM, FI,	AZ, FR,	BY,	
		1370 1370	570			A2		2003	1217	1		002-	7609	92	1	2	0020	228	
			ΙE,	SI,	LT,	LV,	FI,	ES, RO,	MK,	CY,	AL,	TR							
		3523 2004																	
PRIO		Y APP								į į	US 2 US 2 US 2	001-: 001-: 002-:	2721 2780 8694	03P 45P 3	1 1 2	P 2 P 2 A3 2	0010: 0010: 0020:	228 322 228	
AR	The	nre	sent	inv	enti	on ha	9 6	leter	mina			002-							-mi.

The present invention has determined that exogenously added glucosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cofactors that contribute to the antithrombotic activity of the protein C pathway. The present invention has also determined that a deficiency of plasma GlcCer is a risk factor for

thrombosis. Methods are provided to determine individuals at risk for thrombosis, methods of treatment as well as methods of screening for antithrombotic factors from neutral glycolipids.

IT 113665-84-2, Clopidogrel

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(plasma glucosylceramide or other neutral glycolipid deficiency as risk factor for thrombosis and modulator of anticoagulant protein C when given in vesicle form in relation to combination with other agents)

RN 113665-84-2 CAPLUS

CN

Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)|-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1178595 CAPLUS

DOCUMENT NUMBER: 146:740

TITLE: Peptides and peptide mimetics to treat pathologies

characterized by an inflammatory response

INVENTOR(S): Fogelman, Alan M.; Navab, Mohamad

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 143pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PA	rent	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.	!	D	ATE	
	2006 2006						2006		1	WO 2	006-	US14	839		2	0060	418
	W:	CN,	CO,	CR,	CU,	CZ,	AU, DE, ID,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		KZ, MZ,	LC, NA,	LK, NG,	LR, NI,	LS, NO,	LT, NZ, TJ,	LU, OM,	LV, PG,	LY, PH,	MA, PL,	MD, PT,	MG, RO,	MK, RU,	MN, SC,	MW, SD,	MX, SE,
	RW:	VN, AT,	YU, BE,	ZA, BG,	ZM, CH,	ZW CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,
		CF, GM,	CG, KE,	CI, LS,	CM,	GA, MZ,	GN, NA,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,
CN PRIORITY	1375: (APP:	299						1023	1	CN 20 US 20 US 20	005-	67643	31P	·1	20 P 20 P 20	00504	

AB This invention provides novel active agents (e.g. peptides, small organic mols., amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an

inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route. Synthetic procedures are described.

IT 113665-84-2, Clopidogrel

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptides and peptide mimetics for treatment of pathologies characterized by inflammatory response)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α -(2-chlorophenyl)-6,7-dihydro-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

=> d his

L4

L7

(FILE 'HOME' ENTERED AT 10:38:00 ON 20 APR 2007)

FILE 'REGISTRY' ENTERED AT 10:38:17 ON 20 APR 2007

L1 13 S CLOPIDOGREL

L2 1 S CLOPIDOGREL/CN

FILE 'CAPLUS' ENTERED AT 10:38:29 ON 20 APR 2007

FILE 'REGISTRY' ENTERED AT 10:38:40 ON 20 APR 2007

SET SMARTSELECT ON

L3 SEL L2 1- CHEM: 7 TERMS

SET SMARTSELECT OFF

FILE 'CAPLUS' ENTERED AT 10:38:41 ON 20 APR 2007

1562 S L3

L5 1562 S L4 OR CLOPIDOGREL?

E CANCER+ALL/CT

L6 67 S L5 AND (SOLID TUMOR OR CANCER OR NEOPLASM OR CARCINOMA OR SAR

16 S L6 AND PD <=2002

L8 16 FOCUS L7 1-

=> s 15 and glioma

12754 GLIOMA

4294 GLIOMAS

7 GLIOMATA

13833 GLIOMA

(GLIOMA OR GLIOMAS OR GLIOMATA)

L9 0 L5 AND GLIOMA